ARTICLE | Clinical News
Jinarc tolvaptan regulatory update
June 1, 2015 7:00 AM UTC
The European Commission approved Jinarc tolvaptan from Otsuka for autosomal dominant polycystic kidney disease (ADPKD). The vasopressin 2 (V2) receptor antagonist is indicated to slow the progression...